Literature DB >> 10727476

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.

G Giovannoni1, J D O'Sullivan, K Turner, A J Manson, A J Lees.   

Abstract

Hedonistic homeostatic dysregulation is a neuropsychological behavioural disorder associated with substance misuse and addiction. The disorder has been recognised as a consequence of dopamine replacement therapy (DRT) in 15 patients with Parkinson's disease. The syndrome typically develops in male patients with early onset Parkinson's disease, and can occur with orally and subcutaneously administered DRT. These patients take increasing quantities of their DRT, despite increasingly severe drug induced dyskinesias, and may develop a cyclical mood disorder with hypomania or manic psychosis. There is impairment of social and occupational functioning. Tolerance develops to mood elevating effects of DRT and a negative affective withdrawal state occurs if the drugs are withdrawn or doses decreased. The clinical features and guidelines for managing this syndrome are discussed. A set of diagnostic criteria for further investigating this condition is proposed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727476      PMCID: PMC1736875          DOI: 10.1136/jnnp.68.4.423

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  Serial cognitive profiles in levodopa-induced hypersexuality.

Authors:  N S Harvey
Journal:  Br J Psychiatry       Date:  1988-12       Impact factor: 9.319

2.  Levodopa: alterations in behavior.

Authors:  F K Goodwin; D L Murphy; H K Brodie; W E Bunney
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

Review 3.  Cellular and molecular mechanisms of drug dependence.

Authors:  G F Koob; F E Bloom
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

4.  Sinemet "abusers".

Authors:  P A Nausieda
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

5.  Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs.

Authors:  G Rylander
Journal:  Psychiatr Neurol Neurochir       Date:  1972 May-Jun

6.  Psychopathology induced by "speed drugs".

Authors:  E Schiørring
Journal:  Pharmacol Biochem Behav       Date:  1981       Impact factor: 3.533

7.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Authors:  P Limousin; P Krack; P Pollak; A Benazzouz; C Ardouin; D Hoffmann; A L Benabid
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

8.  Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.

Authors:  H P Vogel; R Schiffter
Journal:  Pharmacopsychiatria       Date:  1983-07

9.  Chronic cocaine administration depletes tyrosine hydroxylase immunoreactivity in the rat brain nigral striatal system: quantitative light microscopic studies.

Authors:  M E Trulson; S Babb; J C Joe; J D Raese
Journal:  Exp Neurol       Date:  1986-12       Impact factor: 5.330

10.  Levodopa addiction. A case study.

Authors:  E Tack; G De Cuypere; C Jannes; A Remouchamps
Journal:  Acta Psychiatr Scand       Date:  1988-09       Impact factor: 6.392

View more
  121 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

2.  Management of sexual dysfunction in Parkinson's disease.

Authors:  Gila Bronner; David B Vodušek
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

3.  Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.

Authors:  Daniel Weintraub; Eugenia Mamikonyan; Kimberly Papay; Judith A Shea; Sharon X Xie; Andrew Siderowf
Journal:  Mov Disord       Date:  2011-12-01       Impact factor: 10.338

4.  Zoophilia and impulse control disorder in a patient with Parkinson disease.

Authors:  Gabriela Raina; Maria Graciela Cersosimo; Federico Micheli
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

5.  Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.

Authors:  Hengyi Rao; Eugenia Mamikonyan; John A Detre; Andrew D Siderowf; Matthew B Stern; Marc N Potenza; Daniel Weintraub
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

6.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

Review 7.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

Review 8.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

10.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

Authors:  David Okai; Sally Askey-Jones; Michael Samuel; Sean S O'Sullivan; K Ray Chaudhuri; Anne Martin; Joel Mack; Richard G Brown; Anthony S David
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.